89bio to Participate in the UBS Global Healthcare Conference
89bio (Nasdaq: ETNB) has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 12:30 PM EST, along with one-on-one investor meetings. The presentation will be available via webcast on 89bio's investor website section, with replay access for approximately 30 days after the conference. 89bio is a clinical-stage biopharmaceutical company developing innovative therapies for liver and cardiometabolic diseases.
89bio (Nasdaq: ETNB) ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute UBS. La direzione dell'azienda parteciperà a una chiacchierata informale martedì 12 novembre 2024, alle 12:30 PM EST, insieme a incontri individuali con gli investitori. La presentazione sarà disponibile tramite webcast nella sezione dedicata agli investitori del sito di 89bio, con accesso alla registrazione per circa 30 giorni dopo la conferenza. 89bio è un'azienda biofarmaceutica in fase clinica che sviluppa terapie innovative per malattie epatiche e cardiometaboliche.
89bio (Nasdaq: ETNB) ha anunciado su participación en la próxima Conferencia Global de Salud de UBS. La dirección de la empresa participará en una charla informal el martes 12 de noviembre de 2024, a las 12:30 PM EST, junto con reuniones individuales con inversores. La presentación estará disponible a través de un webcast en la sección de inversores del sitio web de 89bio, con acceso a la repetición durante aproximadamente 30 días después de la conferencia. 89bio es una empresa biofarmacéutica en etapa clínica que desarrolla terapias innovadoras para enfermedades hepáticas y cardiometabólicas.
89bio (Nasdaq: ETNB)는 다가오는 UBS 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2024년 11월 12일 화요일 동부 표준시 기준 오후 12:30에 진행되는 화상 대화에 참여하며, 개인 투자자 회의도 진행됩니다. 프레젠테이션은 89bio의 투자자 웹사이트 섹션을 통해 웹캐스트로 제공되며, 컨퍼런스 후 약 30일간 재생할 수 있습니다. 89bio는 간 및 심혈관 대사 질환을 위한 혁신적인 치료법을 개발하는 임상 단계의 생물 제약 회사입니다.
89bio (Nasdaq: ETNB) a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé UBS. La direction de l'entreprise prendra part à une discussion informelle le mardi 12 novembre 2024, à 12h30 EST, en plus de réunions individuelles avec des investisseurs. La présentation sera disponible par webcast dans la section des investisseurs du site de 89bio, avec un accès à la rediffusion pendant environ 30 jours après la conférence. 89bio est une entreprise biopharmaceutique en phase clinique qui développe des thérapies innovantes pour les maladies hépatiques et cardiométaboliques.
89bio (Nasdaq: ETNB) hat seine Teilnahme an der bevorstehenden UBS Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 12. November 2024, um 12:30 Uhr EST an einem informellen Gespräch teilnehmen und Einzelgespräche mit Investoren führen. Die Präsentation wird über einen Webcast im Investorensegment der Website von 89bio verfügbar sein, mit einem Wiederholungszugang für etwa 30 Tage nach der Konferenz. 89bio ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das innovative Therapien für Leber- und kardiometabolische Erkrankungen entwickelt.
- None.
- None.
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.
The webcast of the presentation will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
When is 89bio (ETNB) presenting at the UBS Global Healthcare Conference 2024?
How long will the replay of 89bio's (ETNB) UBS Conference presentation be available?
What type of presentation will 89bio (ETNB) give at the UBS Healthcare Conference?
Where can investors access 89bio's (ETNB) UBS Conference presentation?
